HER2-Negative Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Breast cancer stands as the most prevalent affliction among women globally, exerting a significant toll on mortality rates. HER2-negative breast cancer encompasses various subtypes, including normal-like breast cancer, luminal A, partial luminal B, and basal-like varieties. Potential inhibitors for treating HER2-negative breast cancer include PI3K inhibitors, AKT inhibitors, and mTOR inhibitors, which effectively suppress the PI3K/AKT signaling pathway. Additionally, small molecule tyrosine kinase inhibitors hinder angiogenesis, while CDK inhibitors, aurora kinase inhibitors, and HDAC inhibitors disrupt the cell cycle. Moreover, drugs targeting breast cancer stem cells have garnered attention, offering innovative strategies for combating HER2-negative breast cancer. The PI3K pathway can be roughly categorized into type I, II, and III, with type I further divided into IA and IB. At the heart of the PI3K/AKT pathway, AKT is regulated by diverse upstream signaling proteins, orchestrat